Peripherally Administered Human Umbilical Cord Blood Cells Reduce Parenchymal and Vascular β -Amyloid Deposits in Alzheimer Mice

Rashid Laboratory for Developmental Neurobiology, Silver Child Development Center, Department of Psychiatry & Behavioral Medicine, University of South Florida, Tampa, FL 33613, USA.
Stem Cells and Development (Impact Factor: 3.73). 07/2008; 17(3):423-39. DOI: 10.1089/scd.2008.0018
Source: PubMed


Modulation of immune/inflammatory responses by diverse strategies including amyloid-beta (Abeta) immunization, nonsteroidal anti-inflammatory drugs, and manipulation of microglial activation states has been shown to reduce Alzheimer's disease (AD)-like pathology and cognitive deficits in AD transgenic mouse models. Human umbilical cord blood cells (HUCBCs) have unique immunomodulatory potential. We wished to test whether these cells might alter AD-like pathology after infusion into the PSAPP mouse model of AD. Here, we report a marked reduction in Abeta levels/beta-amyloid plaques and associated astrocytosis following multiple low-dose infusions of HUCBCs. HUCBC infusions also reduced cerebral vascular Abeta deposits in the Tg2576 AD mouse model. Interestingly, these effects were associated with suppression of the CD40-CD40L interaction, as evidenced by decreased circulating and brain soluble CD40L (sCD40L), elevated systemic immunoglobulin M (IgM) levels, attenuated CD40L-induced inflammatory responses, and reduced surface expression of CD40 on microglia. Importantly, deficiency in CD40 abolishes the effect of HUCBCs on elevated plasma Abeta levels. Moreover, microglia isolated from HUCBC-infused PSAPP mice demonstrated increased phagocytosis of Abeta. Furthermore, sera from HUCBC-infused PSAPP mice significantly increased microglial phagocytosis of the Abeta1-42 peptide while inhibiting interferon-gammainduced microglial CD40 expression. Increased microglial phagocytic activity in this scenario was inhibited by addition of recombinant CD40L protein. These data suggest that HUCBC infusion mitigates AD-like pathology by disrupting CD40L activity.

Download full-text


Available from: Paul Sanberg,
  • Source
    • "HUCBCs induce strong immunomodulatory properties by the host and yet remain weakly immunogenic themselves (Vendrame et al., 2006; Nikolic et al., 2008). As observed in an animal stroke model, HUCBCs inhibit the pro-inflammatory T helper cell type 1 (Th1) response, while promoting a strong anti-inflammatory T helper 2 (Th2) response (Vendrame et al., 2004; Nikolic et al., 2008). Numerous studies having shown that HUCBC treatment of rodents does not elicit GVHD (Graft Versus Host Disease), a leading cause of death in patients that have received stem cell transplants (Li et al., 2001b; Lu et al., 2002; Henning et al., 2004; Hu et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ischemic stroke is responsible for many deaths and long-term disability world wide. Development of effective therapy has been the target of intense research. Accumulating preclinical literature has shown that substantial functional improvement after stroke can be achieved using subacutely administered cell-based and pharmacological therapies. This review will discuss some of the latest findings on bone marrow-derived mesenchymal stem cells (BMSCs), human umbilical cord blood cells, and off-label use of some pharmacological agents, to promote recovery processes in the sub-acute and chronic phases following stroke. This review paper also focuses on molecular mechanisms underlying the cell-based and pharmacological restorative processes, which enhance angiogenesis, arteriogenesis, neurogenesis, and white matter remodeling following cerebral ischemia as well as an analysis of the interaction/coupling among these restorative events. In addition, the role of microRNAs mediating the intercellular communication between exogenously administered cells and parenchymal cells, and their effects on the regulation of angiogenesis and neuronal progenitor cell proliferation and differentiation, and brain plasticity after stroke are described.
    Frontiers in Human Neuroscience 06/2014; 8:382. DOI:10.3389/fnhum.2014.00382 · 3.63 Impact Factor
  • Source
    • "Intravenously -reduced cerebral parenchymal and vascular A␤ plaques -decreased circulating and brain soluble CD40L -elevated systemic IgM levels -reduced CD40+ microglia and GFAP+ astrocytes -increased microglial phagocytosis of A␤ -increased plasma A␤ levels correlated with decreased CD40–CD40L interaction -not tested [97] NSCs 500,000 cells disomic and trisomic Ts65Dn mice Hippocampus unilaterally -reduced tau/reelin-positive granules in the Rad/LM of CA1 -not tested [98] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease represent unmet medical need. There is no effective cure available on the market. Several novel therapeutic approaches targeting fundamental features of these disorders have been proposed during the last two decades. Cell therapy represents one of the most promising therapeutic avenues targeting different pathological traits of these disorders. However, there are some caveats that should be taken into the consideration including ethical issues and limited utilization for routine clinical practice. It is unlikely that cell therapy constitutes the 'magic bullet' therapeutic approach that would meet all therapeutic needs. However, in the future it can potentially bolster the effect of disease modifying drugs by improving the brain environment and regulation of inflammatory and neurotrophic pathways.
    Journal of Alzheimer's disease: JAD 08/2013; 37(2). DOI:10.3233/JAD-130572 · 4.15 Impact Factor
  • Source
    • "Although the method is widely used [4, 26, 59], the irradiation in the chimeric model has been legitimately criticized for causing preconditioning leading to increased permeability of BBB and excessive peripheral cell infiltration into the brain parenchyma [1, 2••]. Other approaches have been to transplant the cells to naive mouse circulation or locally into the brain to study their Aβ phagocytosis [28, 30•, 60]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glial cells in Alzheimer's disease (AD) have been shown to be capable of clearing or at least restricting the accumulation of toxic amyloid beta (Aβ) deposits. Recently, bone marrow (BM)-derived monocytic cells have been recognized in experimental studies to be superior in their phagocytic properties when compared to their brain endogenous counterparts. In human AD, BM-derived monocytic cells may have deficiencies in their capacity to restrict plaque growth. Therefore, enhancement of phagocytic properties of cells of monocyte origin, both brain endogenous microglia and BM-derived monocytic cells, offers an attractive therapeutic approach to fight off AD. Transgenic mouse models with aberrant Aβ deposition offer a valuable tool for discovery of novel pathways to facilitate cell-mediated Aβ uptake. This article reviews the most recent findings on the phagocytic capacity of cells with monocytic origin in various transgenic AD models and describes the methods to study phagocytic activity of these cells.
    03/2012; 1(1):11-20. DOI:10.1007/s13670-011-0004-z
Show more